PTEN Hamartoma Tumor Syndrome Covid-19 Guidance

PHTS is a chronic condition. This does potentially increase the risk for more severe COVID19 course. Among the known risk factor for a more severe course are older age (in particular > 60 years), male gender and presence of chronic conditions such as tumors. Additional factors such as treatment with chemotherapy, immune modulating checkpoint inhibitor treatment or known immune defects that can be associated with PHTS should increase awareness to reduce the infection risk further and should prompt individualized monitoring in case of infection.

Advice provided by Centre of Disease Control and individual state and country should provide guidance. Key is to reduce the contacts to other potentially infected people, wash hands, etc. We suggest discussing continuation and supply of ongoing treatments individually with your doctor, when possible via tele medicine.

In the absence of strong disease specific evidence und a changing epidemiological situation there is only pragmatic general advise one can give to patients with PHTS and all decisions need to be made by the treating clinician.


Note:
Information contained in this document is not to be construed as individual medical advice, please consult your physician if you have specific questions related to your care.